 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com initiated coverage on shares of ARCA biopharma (NASDAQ:ABIO  Free Report) in a research note published on Monday. The brokerage issued a sell rating on the biopharmaceutical...

ARCA biopharma (NASDAQ:ABIO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO  Free Report) in a research report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical...

ARCA biopharma (NASDAQ:ABIO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of ARCA biopharma (NASDAQ:ABIO  Get Free Report) in a report issued on Thursday. The brokerage set a sell rating on the...

ARCA biopharma (NASDAQ:ABIO) Research Coverage Started at StockNews.com

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE...

ARCA biopharma Announces Third Quarter 2023 Financial Results

StockNews.com assumed coverage on shares of ARCA biopharma (NASDAQ:ABIO  Free Report) in a report issued on Wednesday. The firm issued a sell rating on the biopharmaceutical companys...

StockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO)

Stock analysts at StockNews.com started coverage on shares of ARCA biopharma (NASDAQ:ABIO  Get Free Report) in a report issued on Monday. The firm set a sell rating on the...

ARCA biopharma, Inc. (NASDAQ:ABIO  Get Free Report) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 242,000 shares, a drop of 7.0...

ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Down 7.0% in August

Research analysts at StockNews.com assumed coverage on shares of ARCA biopharma (NASDAQ:ABIO  Get Free Report) in a research report issued on Saturday. The brokerage set a sell&#8221...

StockNews.com Initiates Coverage on ARCA biopharma (NASDAQ:ABIO)

Equities research analysts at StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO  Get Free Report) in a note issued to investors on Friday. The firm set a sell&#8221...

ARCA biopharma (NASDAQ:ABIO) Earns Sell Rating from Analysts at StockNews.com

ARCA biopharma, Inc. (NASDAQ:ABIO  Get Free Report)s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.06 and...

ARCA biopharma (NASDAQ:ABIO) Stock Price Passes Below 200 Day Moving Average of $2.06

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Watchers	18,410
52-Wk Low	$1.74
52-Wk High	$2.70

Market Cap	$27.96M
Volume (M)	25,946.00
52-Wk High	$2.70
52-Wk Low	$1.74

ABIO ARCA biopharma Inc

About

Feed

News

Sentiment

Fundamentals